Navigation Links
New Data Shows DaVita Facilities Lead Virginia in Improving Kidney Patient Care
Date:9/15/2009

DENVER, Sept. 15 /PRNewswire-FirstCall/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized in the state of Virginia for reaching the End Stage Renal Disease (ESRD) Network's patient quality improvement goal. DaVita(R) strives to maximize the well-being and health of dialysis patients in Virginia by promoting increased use of fistulas, thereby minimizing the risk of complications.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

The Fistula First Breakthrough Initiative - or the National Vascular Access Improvement Initiative - is a nationwide campaign to increase the use of arterial venous fistulas (AVFs) in dialysis patients, which are believed to reduce infections and improve clinical outcomes. The Fistula First initiative was launched July 1, 2003, by the Centers for Medicare and Medicaid Services (CMS) along with the 18 ESRD Networks and the Institute of Healthcare Improvement (IHI).

ESRD Network 5 monitors dialysis facilities in Virginia and recently recognized those clinics that have reached or are nearing a target fistula usage rate of 50 percent or greater, directionally consistent with nationwide goals of improving outcomes for ESRD patients.

Newly released data shows that DaVita represents 53 percent of all facilities achieving a target fistula usage rate of 50 percent or greater in the state of Virginia. The next best provider represented 34 percent of the recognized facilities - meaning DaVita has 65 percent more facilities that have achieved the target fistula usage rate. Additionally, the DaVita Front Royal Dialysis clinic was just one of three facilities in the state that went above and beyond by reaching an AVF use rate of 70 percent or greater.

The data is also noteworthy because fistula use is one of CMS' four key Clinical Performance Measures of Quality. With its commitment to following these measures and striving for excellence, DaVita's clinical outcomes are consistently the best or among the best in the industry.

"At DaVita, our highest priority is optimizing the health care of the approximately 116,000 patients cared for by our professional partners and teammates," said Allen R. Nissenson, MD, FACP, and Chief Medical Officer of DaVita. "We're pleased that this commitment has once again been validated by CMS' Fistula First findings."

DaVita is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita has been recognized as the only FORTUNE 500(R) company on WorldBlu's annual List of Most Democratic Workplaces(TM). As of June 30, 2009, DaVita operated or provided administrative services at 1,493 outpatient dialysis facilities and acute units in approximately 700 hospitals located in 43 states and the District of Columbia, serving approximately 116,000 patients. As part of DaVita's commitment to building a healthy, caring community, DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. For more information about DaVita, its kidney education materials and its community programs, please visit www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jessica Simpson Shows Support for Breast Cancer Awareness
2. Early Spankings Make for Aggressive Toddlers, Study Shows
3. Poll Shows Liberals Opposed to Extending Taxpayer Funded Healthcare to Illegal Immigrants
4. Breaking Zogby/O'Leary Poll Shows a Sizable Majority of Americans Agree on Eight Critical Health Care Issues
5. Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation
6. HPV Vaccine Study Shows Why Few Women Getting Shots
7. Poll Shows Solid Business Support for Health Care Reform
8. Picking quality health care: New study shows a little context makes a big difference
9. Study Shows 1% of Americans Have Been Infected With West Nile
10. Survey Shows At-Risk Men Lacking In Prostate Cancer Knowledge
11. Lapatinib shows minimal effect against liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... American adults with chronic conditions reported skipping doses or not filling a prescription ... uninsured or under-insured, rates of cost-related problems getting medications were 30-60%*. ...
(Date:2/22/2017)... PA (PRWEB) , ... February 22, 2017 , ... Sideline ... where the company met national TV host Tom Seay and his production crew. ... a favorite among equestrians around the world. Saddle Sidekicks will be featured on ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever National Heart ... advocates, and individuals join together to increase recognition about the risks of heart ... , “Today we mark a nationwide movement to raise awareness about a disease ...
(Date:2/22/2017)... MADISON HEIGHTS, MICHIGAN (PRWEB) , ... February 22, ... ... news and analysis of issues related to spine practices, is featuring Michigan neurosurgeon ... Jagannathan is known as one of a small number of neurosurgeons in Michigan ...
(Date:2/22/2017)... ... 22, 2017 , ... Michael J. Hennessy Associates, Inc. (MJH ... technology professionals and other key stakeholders with an array of valuable resources, Healthcare ... 1, announced Michael J. Hennessy, Jr., president of MJH Associates. , In ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By ... ... is forecasted to grow at a CAGR of 5.33% during 2016-2021 ... of infectious diseases along with surging demand of digital thermometer. Apart ...
(Date:2/22/2017)... Oncternal Therapeutics, Inc., a clinical-stage biotechnology ... common malignancies, today announced the closing of an ... to use the proceeds to further clinical development ... preclinical development of a new ROR1-targeted antibody-drug conjugate ... anti-ROR1 monoclonal antibody being developed to treat patients ...
(Date:2/22/2017)... , Feb. 22, 2017 Kineta, ... development of novel immune modulating therapies, today announced ... a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust chronic ... pain models. The study also establishes the a9a10 ... treatment of chronic pain. The findings were reported ...
Breaking Medicine Technology: